EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Loss of cyclin C drives resistance to anti-TIGIT therapy by upregulating CD155-mediated immune evasion

Shiyu Mao, Yadong Guo, Chengyuan Dong, Dongdong Wang, Xinbo Wang, Linjun Weng, Yanrong Yang, Yaxu Li, Tingting Niu, Qi Wu, Zening Zheng, Zezhi Shan und 8 weitere

Drug Resistance Updates · 2026-01 · 84 · 101318

DOI: 10.1016/j.drup.2025.101318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-01. Verfasst von Shiyu Mao und 19 weiteren Autor:innen. Beteiligte Einrichtung: Tongji University Cancer Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China; Department of Urolog…. Hauptthemen laut MEDLINE: Receptors, Immunologic, Drug Resistance, Neoplasm, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Scientific Instrument and Equipment Development Projects of China, Science and Technology Commission of Shanghai Municipality, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: CD155 is an immune checkpoint protein expressed in tumor cells that interacts with its ligand T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) on natural killer (NK) cells and T cells, mediating inhibitory regulation on immune cells. Blockade of the CD155-TIGIT interaction has demonstrated clinical benefits in patients with advanced cancers. The transcriptional and post-translational mechanisms governing CD155 expression remain largely unknown. METHODS: To identify regulators of CD155, we conducted a genome-wide CRISPR-Cas9 screen in cancer cells. Surface CD155 protein levels were analyzed via flow cytometry. The role of candidate regulators was validated through loss- and gain-of-function experiments with flow cytometry, Western blot, quantitative PCR, and chromatin immunoprecipitation (ChIP) assays. Additionally, ubiquitination assay was performed to examine post-translational modifications. Functional studies, including NK and T cell cytotoxicity assays, were conducted to assess the immune modulatory effects of CD155 regulation. Clinical relevance was evaluated by analyzing Cyclin C (CCNC) and CD155 expression in datasets of cancer patients who underwent immune checkpoint blockade therapy. RESULTS: The CRISPR-Cas9 screen identified CCNC as a transcriptional suppressor of CD155. CCNC knockout led to increased surface CD155 expression in cancer cell lines. Mechanistically, CCNC inhibited CD155 transcription by suppressing the activity of the transcription factor FOSL2. Furthermore, CCNC was found to be ubiquitinated and degraded by the E3 ubiquitin ligase FBXO11, suggesting a post-translational regulatory mechanism. Functionally, loss of CCNC promoted CD155 upregulation, thereby enhancing tumor immune evasion from NK and T cell-mediated responses. Clinically, CCNC expression was negatively correlated with CD155 levels in cancer patients, particularly those receiving immune checkpoint blockade therapy. CONCLUSION: This study identifies a previously unrecognized master regulator CCNC that functions as a suppressor of CD155-mediated cancer immune evasion. The findings of this study suggest that tumors with low CCNC expression may be resistant to monotherapy and highlight a combination immunotherapy (TIGIT/PD-1 co-blockade) as a promising anti-cancer therapeutic strategy to overcome immune evasion in CCNC-deficient tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ImmunologicDrug Resistance, NeoplasmNeoplasmsHumansKiller Cells, NaturalCell Line, TumorUp-RegulationCRISPR-Cas SystemsT-LymphocytesGene Expression Regulation, NeoplasticImmune EvasionImmune Checkpoint InhibitorsTumor EscapeReceptors, Virus

Stichwörter der Autor:innen

Immune checkpoint CD155ImmunotherapyTranscriptional regulationUbiquitination

Substanzen

Receptors, ImmunologicTIGIT protein, humanpoliovirus receptorImmune Checkpoint InhibitorsReceptors, Virus

Autor:innen und Institutionen

  • Tongji University Cancer Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China; Department of Urology, Urologic Cancer Institute, Shanghai Tenth People's Hospital, Tongji…
  • Tongji University Cancer Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China; Medical College, Anhui University of Science and Technology, Huainan 232001, China.
  • Tongji University Cancer Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
  • Tongji University Cancer Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China; Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032…
  • Department of Pathology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
  • Tongji University Cancer Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China. Electronic address: xin.ge@tongji.edu.cn.

Förderung

  • National Key Scientific Instrument and Equipment Development Projects of China
  • Science and Technology Commission of Shanghai Municipality
  • National Key Research and Development Program of China
  • Shanghai Science and Technology Development Foundation
  • Tongji University
  • National Natural Science Foundation of China

Zitieren

APA

Mao, S., Guo, Y., Dong, C., Wang, D., Wang, X., Weng, L., Yang, Y., Li, Y., Niu, T., Wu, Q., Zheng, Z., Shan, Z., Tan, X., Gao, Y., Jin, J., Wang, P., Ge, X., Shen, B., Yao, X., & Fang, L. (2026). Loss of cyclin C drives resistance to anti-TIGIT therapy by upregulating CD155-mediated immune evasion. Drug Resistance Updates, 84, 101318. https://doi.org/10.1016/j.drup.2025.101318

Vancouver

Mao S, Guo Y, Dong C, Wang D, Wang X, Weng L, et al. Loss of cyclin C drives resistance to anti-TIGIT therapy by upregulating CD155-mediated immune evasion. Drug Resistance Updates. 2026;84:101318. doi:10.1016/j.drup.2025.101318

BibTeX
@article{Mao2026,
  author = {Mao, Shiyu and Guo, Yadong and Dong, Chengyuan and Wang, Dongdong and Wang, Xinbo and Weng, Linjun and Yang, Yanrong and Li, Yaxu and Niu, Tingting and Wu, Qi and Zheng, Zening and Shan, Zezhi and Tan, Xiao and Gao, Yaohui and Jin, Jiali and Wang, Ping and Ge, Xin and Shen, Bing and Yao, Xudong and Fang, Lan},
  title = {Loss of cyclin C drives resistance to anti-TIGIT therapy by upregulating CD155-mediated immune evasion},
  journal = {Drug Resistance Updates},
  year = {2026},
  volume = {84},
  pages = {101318},
  doi = {10.1016/j.drup.2025.101318}
}
Kostenlos starten →